Roni Wechsler
Keine laufenden Positionen mehr
Profil
Roni Wechsler worked as Projects Director at Quark Pharmaceuticals, Vice President-Research & Development at Regentis Biomaterials Ltd., and Chief Technology Officer at both ProChon Biotech Ltd.
and Procore Project Solutions Ltd.
He received his undergraduate degree from McGill University and his graduate and doctorate degrees from Weizmann Institute of Science.
Ehemalige bekannte Positionen von Roni Wechsler
| Unternehmen | Position | Ende |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | - |
Procore Project Solutions Ltd.
 Procore Project Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Drees & Sommer SE, Procore Project Solutions Ltd. provides consultancy services in the field of facility management, workplace consulting and tenant management. Procore Project Solutions was acquired by Drees & Sommer SE on May 18, 2017. | Technik-/Wissenschafts-/F&E-Leiter | - |
ProChon Biotech Ltd.
 ProChon Biotech Ltd. Pharmaceuticals: MajorHealth Technology ProChon Biotech, Ltd. manufactures innovative growth factor-based therapies in regenerative medicine and orthopedics. The company was founded by Avner Yayon in 1995 and is headquartered in Tel Aviv, Israel. | Technik-/Wissenschafts-/F&E-Leiter | - |
Regentis Biomaterials Ltd.
 Regentis Biomaterials Ltd. BiotechnologyHealth Technology Regentis Biomaterials Ltd. engages in the research and development of proprietary hydrogels for local repair of damaged cartilage and bone. Its product is GelrinC. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Roni Wechsler
| McGill University | Undergraduate Degree |
| Weizmann Institute of Science | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. BiotechnologyHealth Technology Regentis Biomaterials Ltd. engages in the research and development of proprietary hydrogels for local repair of damaged cartilage and bone. Its product is GelrinC. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel. | Health Technology |
ProChon Biotech Ltd.
ProChon Biotech Ltd. Pharmaceuticals: MajorHealth Technology ProChon Biotech, Ltd. manufactures innovative growth factor-based therapies in regenerative medicine and orthopedics. The company was founded by Avner Yayon in 1995 and is headquartered in Tel Aviv, Israel. | Health Technology |
Procore Project Solutions Ltd.
Procore Project Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Drees & Sommer SE, Procore Project Solutions Ltd. provides consultancy services in the field of facility management, workplace consulting and tenant management. Procore Project Solutions was acquired by Drees & Sommer SE on May 18, 2017. | Commercial Services |
